Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Status:
Completed
Trial end date:
2017-10-09
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well cabozantinib-s-malate works in treating patients with
thyroid cancer that does not respond to treatment. Cabozantinib-s-malate may stop the growth
of thyroid cancer by blocking some of the enzymes needed for cell growth.
Cabozantinib-s-malate may also stop the growth of thyroid cancer by blocking blood flow to
the tumor.